# Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer

> **NCT01827163** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 20 (actual)

## Conditions studied

- HER2-Positive Early Stage Breast Cancer

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Trastuzumab
- **DRUG:** Lapatinib
- **DRUG:** Pegfilgrastim

## Key facts

- **NCT ID:** NCT01827163
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2019-01
- **Final completion:** 2019-01
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2019-12-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01827163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01827163, "Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT01827163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*